Abstract:Abstract Background: Long-term survivors of childhood cancer experience high rates of patient-reported symptoms and evidence for accelerated molecular aging. Both are established to increase the risk for late-mortality (>5 years from cancer diagnosis). We aim to investigate if accelerated molecular aging mediates the association between symptoms and all-cause late-mortality. Methods: DNA methylation (DNAm)-based aging biomarkers were derived from the DNAm Age Calculator, including epigenetic age acceleration (EAA) using multiple clocks (e.g., GrimAge and PhenoAge) and other DNAm-predicted biomarkers (e.g., DNAmB2M: beta-2-microglobulin, DNAmTL: telomere length) adjusted for age and standardized. Survivors self-reported the presence of 10 symptom domains (cardiac, pulmonary, sensory, motor/movement, nausea, pain, fatigue, memory, anxiety, and depression) that were aggregated into a total symptom burden score. Multiple linear regression tested the association between each aging biomarker and symptom prevalence, adjusting for the age of symptom survey, sex, and cancer treatment exposures. Cox regression tested the association of each aging biomarker or symptom domain with mortality. Aging biomarkers mediation for the symptom-mortality association was assessed by using the Accelerated Failure Time model and the mediation R package. False discovery rate was controlled for multiple testing. Results: Among 2,206 survivors (47% males) who had DNAm measured on (52%) or after the survey, the median duration from the symptom survey to DNA sampling were 0.48 years (IQR: 0.09-4.27 years). EAA_GrimAge was the aging biomarker most closely associated with total symptom burden (beta [95%CI] = 0.576 [0.455, 0.697] years, P=2.89×10-18) and eight of ten domain-specific symptoms except for motor/movement and memory. Seven aging biomarkers (e.g., DNAmB2M: 1.91 [1.48, 2.48], P=1.87×10-5; EAA_GrimAge: HR [95%CI] = 1.17 [1.09, 1.26], P=3.1×10-4 ) and five symptom domains (e.g., pulmonary: 2.54 [1.44, 4.49], P=0.004; cardiac: 2.25[1.28, 3.97], P=0.01; total symptom burden: 1.47 [1.18, 1.82], P=0.0019) were associated with mortality risk. EAA (e.g., EAA_GrimAge) mediated the association between symptoms (cardiac: % mediation =0.13 [0.044, 0.379], P=0.008; pulmonary: 0.186 [0.075, 0.486], P=0.008; and total symptoms: 0.206 [0.078, 0.503], P=0.012) and late mortality. In addition, the association between symptoms and mortality was mediated by DNAmB2M and DNAmTL (e.g., pulmonary: 0.152 [0.046, 0.378], P=0.008; 0.12 [0.031, 0.373], P=0.021). Conclusions: EAA, DNAmB2M and DNAmTL mediated the association between the presence of specific symptom domains and late-mortality, suggesting that accelerated molecular aging may be an underlying biological pathway explaining the associations between symptom burden and mortality. Citation Format: Qian Li, Yue Pan, Xijun Zhang, Noel-Marie Plonski, g Chen, Qian Dong, Kyla Shelton, John Easton, Heather Mulder, Jinghui Zhang, Geoffrey Neale, Emily Walker, Deo Kumar Srivastava, Greg T. Armstrong, Kirsten Ness, I-Chan Huang, Zhaoming Wang. DNA methylation based aging biomarkers mediate the association between patient-reported symptoms and all-cause late-mortality: A report from the St. Jude Lifetime Cohort [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6384.

DNA Methylation-Based Biomarkers of Age Acceleration and All-Cause Death, Myocardial Infarction, Stroke, and Cancer in Two Cohorts: the NAS, and KORA F4

DNA methylation GrimAge strongly predicts lifespan and healthspan

DNA methylation age of blood predicts all-cause mortality in later life

DNAm-based Signatures of Accelerated Aging and Mortality in Blood Are Associated with Low Renal Function.

Abstract P271: Dna Methylation Measures of Aging in Midlife Are Associated with Frailty Components in African American and European American Older Adults: the Atherosclerosis Risk in Communities (ARIC) Study

Accelerated DNA methylation age plays a role in the impact of cardiovascular risk factors on the human heart

Integrative analysis of clinical and epigenetic biomarkers of mortality

DNA methylation-based measures of biological aging and cognitive decline over 16-years: preliminary longitudinal findings in midlife

Genome-wide association studies identify 137 genetic loci for DNA methylation biomarkers of aging

Quantification of the pace of biological aging in humans through a blood test: The DunedinPoAm DNA methylation algorithm

Blood DNA Methylation Sites Predict Death Risk in a Longitudinal Study of 12, 300 Individuals

Modeling biological age using blood biomarkers and physical measurements in Chinese adults

NMR metabolomics-guided DNA methylation mortality predictors

EPIGENETIC PREDICTORS OF LIFESPAN AND HEALTHSPAN

Comparative validation of three DNA methylation algorithms of ageing and a frailty index in relation to mortality: results from the ESTHER cohort study

Correction for: Accelerated DNA methylation age and the use of antihypertensive medication among older adults.

Genome-wide association studies identify 137 loci for DNA methylation biomarkers of ageing

Epigenetic and Metabolomic Biomarkers for Biological Age: A Comparative Analysis of Mortality and Frailty Risk

Mortality Associations With DNA Methylation-Based Biological Aging and Physical Functioning Measures Across a 20-Year Follow-up Period

DNA methylation age acceleration is associated with incident cognitive impairment in the Health and Retirement Study

Abstract 6384: DNA Methylation Based Aging Biomarkers Mediate the Association Between Patient-Reported Symptoms and All-Cause Late-Mortality: A Report from the St. Jude Lifetime Cohort